# Cizzle Biotechnology Advancing Lung Cancer Detection from R&D to Application with Moffitt Cancer Centre (VIDEO)

- Link: https://www.directorstalkinterviews.com/cizzle-biotechnology-advancing-lung-cancer-detection-from-rd-to-application-with-moffitt-cancer-centre-video/4121171201
- Published: 2024-09-10T08:55:11+01:00
- Author: Emily Johnson

**Cizzle Biotechnology plc** (LON:CIZ) Executive Chairman Dr Allan Syms joins DirectorsTalk
Interviews to discuss a collaboration with Moffitt Cancer Center the number one 
cancer hospital in Florida and the Southeast USA.

In this insightful interview, Dr Allan Syms, Executive Chairman of Cizzle Biotechnology,
shares key updates on the company’s latest collaboration with Moffitt Cancer Centre,
a renowned institution in lung cancer treatment. He discusses the strategic significance
of this partnership and the role of the CIZ1B biomarker in improving early detection
of lung cancer. Dr Syms also addresses the potential impact of the biomarker on 
existing screening methods, the competitive landscape, and the future outlook for
Cizzle Biotechnology. This conversation highlights the company’s transition from
research and development to market application, offering a glimpse into its promising
future.

Cizzle Biotechnology is a UK based developer of a blood test for the early detection
of a majority of different forms of lung cancer.

Share on:
